Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
    Technology 7/19/2023

    KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
    View this post in the Community →

    Similar Community Posts Join

    6 / 189 results

    Related Research

    6 / 125 results